(Reuters) - AcelRX Pharmaceuticals Inc said its experimental treatment for post-operative pain met its main goal in a late-stage trial of patients who had undergone knee or hip replacement surgery, sending its shares up 15 percent. AcelRX said its Sufentanil NanoTab PCA System showed a decrease in pain intensity, compared with a placebo, as measured on a clinical scale 48 ...

(Reuters) - AcelRX Pharmaceuticals Inc said its experimental drug device to treat post-operative pain met the main goal of controlling pain in a late-stage study among patients who had undergone knee or hip replacement surgery. Shares of the company rose 31 percent to $8.44 in trading before the bell. The device showed that the drug showed a decrease in pain ...

New blood test can find allergies before implant surgery.        

WebMD helps you decide whether a hip or knee replacement is right for you.